Alumis (ALMS) Other Non Operating Income (2023 - 2026)
Alumis' (ALMS) quarterly Other Non Operating Income came in at -$71000.0 in Q2 2026, down 100.04% year-over-year from $187.9 million in Q2 2025, and down 31.48% quarter-over-quarter from -$54000.0 in Q3 2025.
Analysis
Alumis (ALMS) Other Non Operating Income (2023 - 2026) Analysis & Trends
Alumis (ALMS) has reported Other Non Operating Income for 4 consecutive years, with -$71000.0 the latest figure, recorded in Q2 2026.
- On a quarterly basis, Other Non Operating Income fell 100.04% year-over-year to -$71000.0 in Q2 2026; TTM through Jun 2026 was $187.8 million, a 7.38% decrease from a year earlier, with the FY2025 full-year figure at $187.9 million, up 1873.81% from the prior year.
- Other Non Operating Income was -$71000.0 for Q2 2026 at Alumis, down from -$54000.0 in the prior quarter.
- Over five years, Other Non Operating Income peaked at $187.9 million in Q2 2025 and troughed at -$3.1 million in Q1 2024.
- A 4-year average of $19.7 million and a median of -$49000.0 in 2025 frame the typical range for Other Non Operating Income.
- Across the five-year window, Other Non Operating Income sank 634.95% in 2024 and soared 8230.98% in 2025, its largest moves.
- Over 4 years, Other Non Operating Income stood at -$551000.0 in 2023, then surged by 2808.89% to $14.9 million in 2024, then slumped by 100.36% to -$54000.0 in 2025, then slumped by 31.48% to -$71000.0 in 2026.
- The last three Other Non Operating Income figures came in at -$71000.0 (Q2 2026), -$54000.0 (Q3 2025), and $187.9 million (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | Alumis | 1.27 Bn | 765.76 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -71,000.00 |
| Sep 30, 2025 | -54,000.00 |
| Jun 30, 2025 | 187.91 Mn |
| Mar 31, 2025 | -44,000.00 |
| Dec 31, 2024 | 14.93 Mn |
| Sep 30, 2024 | -40,000.00 |
| Jun 30, 2024 | -2.31 Mn |
| Mar 31, 2024 | -3.10 Mn |
| Sep 30, 2023 | -551,000.00 |
| Jun 30, 2023 | 432,000.00 |